London (PRWEB UK) 10 April 2013
In a recent clinical trial, 60 subjects aged between 40 and 75 with moderate to severe osteoarthritis of the hip and knee were administered Inflavestin, a proprietary blend of Scutellaria biacalensis and Acacia catechu. In the randomized, double blind, placebo and active comparator study the subjects were allocated into four groups and all assigned varying levels of the ingredient, a placebo or Celecoxib, a prescription only non-steroidal anti-inflammatory drug used in the treatment of osteoarthritis pain.
Subjects were measured using the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) score at 30, 60 and 90 days and a statistically significant decrease in stiffness shown in the groups using Inflavestin. No decrease in stiffness was shown in the groups not receiving the ingredient. There was also a statistically significant improvement in physical function and endurance for the groups taking Inflavestin.
Inflavestin is available in the UK as an ingredient in Osteoplan, a 4 part treatment plan for osteoarthritis. The plan follows the guidance of the National Institute for Health and Clinical Excellence which recommends a multi-modal approach to the treatment of osteoarthritis symptoms.
Osteoplan comprises a non-pharmaceutical pain relief device based around vibration therapy, a course of tablets consisting of Inflavestin combined with three common ingredients of glucosamine, MSM and chondroitin, and a highly absorbent glucosamine based gel. The fourth part consists of regular monitoring by a medical professional using a patient feedback diary, help and advice on managing the patients condition and assistance with weight-loss and exercise.
With Inflavestin showing significant benefits in its most recent clinical trial, and Osteoplan following NICE guidelines, the plan has been accepted as a significant step forward in the drug free treatment of osteoarthritis pain.
MLE Medical Team.